Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis

Ultragenyx is a commercial-stage rare-disease biotech that has evolved into a multi-product company with four approved therapies (Crysvita, Dojolvi, Mepsevii, Evkeeza ex-U.S.). 2025 revenue reached ~$673M (+20% YoY), led by Crysvita (~$481M) and supported by Dojolvi (~$96M) and fast-growing Evkeeza territories (~$59M). The model is differentiated by a mix of direct international sales and meaningful royalty streams from major partners, plus owned infrastructure including gene therapy manufacturing. Despite strong growth, the company posted a large 2025 net loss (~$575M) and is now restructuring to reduce opex ~15% by 2027, targeting GAAP profitability in 2027. Near-term value hinges on 2026–2027 regulatory outcomes for gene therapies (DTX401, UX111) and a pivotal 2026 Phase 3 readout for GTX-102 in Angelman syndrome that could meaningfully expand the company’s commercial scale.